DS-1971a + placebo + pregabalin
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuropathic Pain
Conditions
Neuropathic Pain, Diabetes
Trial Timeline
Feb 1, 2016 → Feb 1, 2017
NCT ID
NCT02673866About DS-1971a + placebo + pregabalin
DS-1971a + placebo + pregabalin is a phase 2 stage product being developed by Daiichi Sankyo for Neuropathic Pain. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02673866. Target conditions include Neuropathic Pain, Diabetes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02673866 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Neuropathic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| OK-101 0.05% + OK-101 0.1% + Placebo | OKYO Pharma | Phase 2 | 44 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| pregabalin sustained release tablet + pregabalin immediate release capsule | Yuhan | Approved | 85 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Placebo + Mirogabalin | Daiichi Sankyo | Phase 3 | 77 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| Duloxetine + Pregabalin + Placebo | Shionogi | Approved | 85 |
| LY3016859 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4065967 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3848575 + Placebo | Eli Lilly | Phase 2 | 52 |
| ABT-639 + pregabalin + Placebo | AbbVie | Phase 2 | 52 |
| onabotulinum toxin A | AbbVie | Phase 2 | 52 |